Opportunity

REDEFINING THE FUTURE OF HEALTHCARE

OptiRTP has created a breakthrough digital therapeutic designed to activate the body’s natural repair pathways. It is already trusted by world champions and those managing chronic conditions. This is an FDA-registered medical technology:
clinically aligned, non-invasive, drug-free, and built to scale globally.

The Problem

When the body’s stress–recovery system becomes imbalanced, the result is chronic dysregulation — leading to pain, poor sleep, fatigue, and stress. This undermines quality of life for millions while draining healthcare resources.
$600B+ annual cost in the U.S. alone: pain, stress, poor sleep, and fatigue drive an unsustainable financial and societal burden.
Over-reliance on drugs: opioids, sedatives, and pain medications are costly, carry serious addiction risks, and lose effectiveness over time.
Non-drug alternatives fall short: therapies are either clinically validated but hard to scale, or easy to scale but lacking validation.
What’s missing is a non-invasive, measurable therapeutic solution that can scale globally — and align with reimbursement pathways.

The Solution

Optimum Bio Sound Therapy delivers a proprietary modulation of ultra-low frequencies carried within sound — inaudible to the ear, yet undeniable in effect.
Clinically aligned: FDA Registered Class I Medical Device since 2021, indicated for pain relief and accelerated wound recovery; advancing toward Class II neuromodulation for expanded claims and reimbursement positioning.
Proven over a decade: 45,000+ hours of R&D; and 200,000+ hours of biofeedback, AI-refined from billions of datapoints into a proprietary therapeutic signal library.
Real-world trust: already used by Olympians, Paralympians, and national sporting captains to accelerate recovery and improve performance.
Next-generation delivery: transitioning from supervised iPad onboarding to low-cost Android automation + OEM earbuds, enabling free trials, viral adoption, and multi-user applications across homes and clinical environments.

This is not wellness “sound therapy.” It is regulated therapeutic technology: clinically aligned, commercially ready, and protected by a proprietary architecture.

The Commercial Opportunity

Year 1 – United States + New Zealand (2026)

  • Autonomous Android launch with $30 OEM earbuds and viral 7-day proof funnel (four staged 7-day cycles).
  • Dual-market entry: subscriber growth in both NZ and U.S., leveraging proof-of-effect biometric overlays and voluntary testimonial sharing.
  • Clinical ignition: initiate the VA Augusta Phantom Limb Pain (PLP) study in June 2026, combining PROMIS tools with biometric capture to maximize credibility.
  • Revenue traction: viral adoption validated in NZ; U.S. subscriber base builds ahead of reimbursement, strengthening credibility with payors.

Year 2 – U.S. Reimbursement Pathway (2027)

  • Completion of VA PLP study with publication in early 2027.
  • Study results unlock reimbursement cascade: VA → Medicare/Medicaid → commercial insurers.
  • Scale-up of U.S. subscriber base on SaaS economics (65–70% margins, viral multiplier adoption).
  • Preparation for FDA Class II neuromodulation relabeling.

Year 3 – Japan (2028)

  • Expansion into the elder-care and resilience markets.
  • Regulatory reciprocity and strong cultural alignment with Japan’s health system.
  • Distribution through local licensing and strategic partners.

This staged approach — viral adoption in Year 1 (NZ + U.S.), reimbursement ignition in Year 2, and global expansion in Year 3 — powers a compounding licensing engine. Each market drives recurring license fees back to OptiRTP, accelerating global revenue growth.

IPO Pathway

OptiRTP's pathway to IPO is clear and achievable

$100M ARR at scale translates to a $1B valuation (10× multiple).

This requires only ~167,000 global subscribers — a fraction of the addressable market.

Perspective:

Among U.S. Veterans Affairs enrollees (~9M, with ~4.5M experiencing chronic pain), only 3.7% penetration is required.

Among Japan’s elderly population (36M aged 65+, ~10M with chronic pain), only 1.7% penetration is required.

The Current Raise

We are raising NZD $1.4M in new equity capital.

The foundations are laid, the inflection point is here.

This is more than a company — it’s a movement to transform healthcare at scale.

Join us.

Legal Notice

This page is for informational purposes only and does not constitute an offer of securities. Forward-looking statements involve risks and uncertainties. Individual experiences vary. Always follow the instructions for use of Optimum Bio Sound Therapy.

Interested in learning more?

Click the button below to sign required disclosures and receive more details

More Information